Concepedia

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

Ronald Emkey, Pierre D. Delmas, Michael A. Bolognese, João Lindolfo Cunha Borges, Felicia Cosman, Sergio Ragi-Eis, Christopher Recknor, Cristiano A. F. Zerbini, Colin Neate, Farhad Sedarati,

Clinical Therapeutics · 2009 · 32 citations · 18 references

DOI

Concepts

References

18

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

Dennis M. Black, Steven R. Cummings, David Karpf et al. · The Lancet · 1996 · 3.9K citations

, , +12

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Steven T. Harris · JAMA · 1999 · 2.5K citations

, , +16

Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures<SUBTITLE>Results From the Fracture Intervention Trial</SUBTITLE>

S. R. Cummings · JAMA · 1998 · 2.3K citations

, , +16

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Jean‐Yves Reginster, H. W. Minne, O. H. Sørensen et al. · Osteoporosis International · 2000 · 1.6K citations

, , +14

Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis

Charles H. Chesnut, Arne Skag, Claus Christiansen et al. · Journal of Bone and Mineral Research · 2004 · 1.2K citations · Full text

, , +16